Dafna D Gladman, Philip J Mease, Laure Gossec, M Elaine Husni, Alice B Gottlieb, Barbara Ink, Rajan Bajracharya, Jason Coarse, Nikos Lyris, Jérémy Lambert, William Tillett
{"title":"Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies.","authors":"Dafna D Gladman, Philip J Mease, Laure Gossec, M Elaine Husni, Alice B Gottlieb, Barbara Ink, Rajan Bajracharya, Jason Coarse, Nikos Lyris, Jérémy Lambert, William Tillett","doi":"10.3899/jrheum.2024-0923","DOIUrl":"10.3899/jrheum.2024-0923","url":null,"abstract":"<p><strong>Objective: </strong>To assess the longer-term effect of bimekizumab up to 1 year on patient-reported symptoms, health-related quality of life (HRQOL), and work productivity in patients with active PsA who were biologic disease-modifying antirheumatic drug (bDMARD)-naïve or had inadequate response/intolerance to tumor necrosis factor inhibitors (TNFi-IR).</p><p><strong>Methods: </strong>BE OPTIMAL (ClinicalTrials.gov: NCT03895203; bDMARD-naïve patients) and BE COMPLETE (NCT03896581; TNFi-IR patients) are phase III studies of subcutaneous bimekizumab 160 mg every 4 weeks. Both studies were double-blind and placebo-controlled to 16 weeks. Patients who completed week 52 of BE OPTIMAL or week 16 of BE COMPLETE were eligible for the open-label extension, BE VITAL (NCT04009499), during which all patients received bimekizumab. Patient-reported pain, fatigue, physical function, HRQOL, and work productivity are reported to week 52 or 40 (52/40) using individual study data for bimekizumab and placebo treatment arms.</p><p><strong>Results: </strong>Bimekizumab-randomized patients demonstrated sustained mean improvements from baseline in patient-reported outcomes to week 52/40, including pain (visual analog scale [0-100 mm]: bDMARD-naïve -30.5; TNFi-IR -31.8), fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue scale [0-52]: bDMARD-naïve 5.3; TNFi-IR 6.0), physical function (Health Assessment Questionnaire-Disability Index [0-3]: bDMARD-naïve -0.34; TNFi-IR -0.39), and HRQOL (36-item Short Form Health Survey, physical component summary: bDMARD-naïve 8.1; TNFi-IR 8.4); placebo patients who switched to bimekizumab at week 16 demonstrated comparable levels of improvement from week 16 to week 52/40. Improvements in overall work impairment were sustained among bimekizumab-randomized patients to week 52. Similar trends were observed for absenteeism, presenteeism, and activity impairment.</p><p><strong>Conclusion: </strong>Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms, HRQOL, and work productivity up to 1 year in bDMARD-naïve and TNFi-IR patients with active PsA.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cheryl Roumen, Laura M Hochstenbach, Pim van den Dungen, Anouk M Knops, Maria Bj Brokken-Peters, Marieke D Spreeuwenberg, Harald E Vonkeman, Astrid van Tubergen
{"title":"Development of an application for self-monitoring to empower patients with rheumatoid arthritis (MyRA).","authors":"Cheryl Roumen, Laura M Hochstenbach, Pim van den Dungen, Anouk M Knops, Maria Bj Brokken-Peters, Marieke D Spreeuwenberg, Harald E Vonkeman, Astrid van Tubergen","doi":"10.3899/jrheum.2024-1071","DOIUrl":"10.3899/jrheum.2024-1071","url":null,"abstract":"<p><strong>Objective: </strong>To develop a web-based self-monitoring tool including motivational elements to improve empowerment of patients with rheumatoid arthritis.</p><p><strong>Methods: </strong>Following a design thinking approach, the development included three iterative, co-creative phases involving different stakeholders. In the 'empathise and define' phase, two focus groups gave insight into patients' wishes and needs regarding self-monitoring with an application. During the 'ideation' phase, two co-creation sessions were organised to establish the content and consider motivational elements. For the 'prototyping and testing' phase, usability was assessed through both formative (heuristics evaluation) and summative (System Usability Scale, 0-100, ≥68 is good to excellent) evaluations.</p><p><strong>Results: </strong>The focus groups resulted in a shortlist of what to monitor (physical possibilities, quality of life, pain, fatigue, mental wellbeing, and social participation) and preferences on how to monitor (single item questions, 0-10 scale, frequency not fixed). The co-creation sessions revealed preference for empathetic dialogues with an avatar for self-monitoring. Setting goals, adding notes, sharing results, and receiving tips could further increase motivation for use. Initial experiences regarding heuristics of the tool were generally positive and confirmed by a System Usability Scale score of 84.4 (SD 11.6). Points for improvement included simplifying login procedures, adding notifications, and adjusting the avatar's tone of voice.</p><p><strong>Conclusion: </strong>A web-based self-monitoring application (MyRA) was developed, with an avatar asking patients in dialogues to score six domains, showing graphical displays, a diary functionality, and practical tips. Further studies are needed to confirm its usability and effectiveness in empowering patients.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Parathyroid Adenoma Presenting as Femoral Tumor Lesion in a 27-Year-Old Woman.","authors":"Anastasia Mocritcaia, Pilar Peris","doi":"10.3899/jrheum.2024-0245","DOIUrl":"10.3899/jrheum.2024-0245","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"293"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas Audet, Marie-Aude Picard-Turcot, Julie Robindaine, Nathalie Carrier, Pierre Dagenais
{"title":"Improving Gout Care in a Canadian Academic Medical Center Through a Multidisciplinary, Nurse-Led Protocol.","authors":"Thomas Audet, Marie-Aude Picard-Turcot, Julie Robindaine, Nathalie Carrier, Pierre Dagenais","doi":"10.3899/jrheum.2024-0707","DOIUrl":"10.3899/jrheum.2024-0707","url":null,"abstract":"<p><strong>Objective: </strong>Following Health Canada's knowledge translation framework, we report the results of a clinical audit from 2012 to 2015 followed by a multidisciplinary, nurse-led gout care protocol with a treat-to-target (T2T) strategy implemented in April 2018.</p><p><strong>Methods: </strong>A clinical audit with chart reviewing was completed for adults with gout and urate-lowering therapy (ULT) indication at the Centre Hospitalier Universitaire de Sherbrooke. A nurse-led treatment algorithm using allopurinol was then developed. Titration of ULT by a nurse every 4 weeks was done until serum uric acid (SUA) target. In the postprotocol implementation, adults with gout and ULT indication were retrospectively recruited through a billing agency until December 2020. The main outcome was SUA target achievement at 6 months.</p><p><strong>Results: </strong>Of 50 patients identified in the audit, 31% reached SUA target at 6 months and 16% were lost to follow-up. A 74-patient postprotocol implementation cohort was recruited, with 43 in the protocol group and 31 under usual care. Most prevalent ULT indication was ≥ 2 gout attacks per year (n = 52) at 70%. Target SUA was reached in 65% (n = 28) in the protocol group at 6 months compared to 19% (n = 6) in the usual care group (<i>P</i> < 0.001). Failing to titrate medication in the usual care group was the leading cause for nonachievement of SUA target at 6 months. Five percent of patients were lost to follow-up, all in the usual care group.</p><p><strong>Conclusion: </strong>A multidisciplinary, nurse-led protocol with a T2T strategy implemented after a clinical audit significantly improved gout care. Such protocol could be replicated elsewhere in Canada.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"285-289"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effective Use of Apremilast in Refractory Arthritis Associated With Cystic Fibrosis.","authors":"Angelo Nigro","doi":"10.3899/jrheum.2024-0978","DOIUrl":"10.3899/jrheum.2024-0978","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"294-295"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sahil Koppikar, Bindee Kuriya, Jacob A Udell, Bing Yu, Anna Chu, Douglas S Lee, Jessica Widdifield, Lihi Eder
{"title":"Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study.","authors":"Sahil Koppikar, Bindee Kuriya, Jacob A Udell, Bing Yu, Anna Chu, Douglas S Lee, Jessica Widdifield, Lihi Eder","doi":"10.3899/jrheum.2024-0866","DOIUrl":"10.3899/jrheum.2024-0866","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the risk of heart failure (HF) in patients with immune-mediated inflammatory diseases (IMIDs) compared to the general population with and without diabetes mellitus (DM).</p><p><strong>Methods: </strong>A population-based cohort study was conducted in patients with rheumatoid arthritis (RA), radiographic axial spondyloarthritis (r-axSpA), psoriatic arthritis, and psoriasis (PsO) in Ontario from 2011 until 2019. The study outcome was first hospitalization for HF. Incidence rates of HF were calculated for each cohort. Hazard ratios (HRs) for HF were calculated using Cox proportional hazard models. The etiology of HF was descriptively classified into mutually exclusive groups based on comorbidities during HF hospitalization.</p><p><strong>Results: </strong>A total of 243,061 patients with IMID, 748,517 with DM, and 8,278,934 non-IMID, non-DM controls were analyzed. The crude incidence rate for HF in IMID was 2.70 per 1000 person-years, with the highest rate in RA and lowest in r-axSpA. The risk of being hospitalized for HF was higher in IMID compared with non-IMID comparators (HR 1.34, 95% CI 1.30-1.38). This risk was highest among patients with RA (HR 1.61, 95% CI 1.54-1.68) and lowest in PsO (HR 1.09, 95% CI 1.03-1.15). In comparison, the risk of HF hospitalization in patients with DM was higher (HR 2.19, 95% CI 2.16-2.21). The most common antecedent comorbidity associated with HF in all patients with IMID was ischemic heart disease. In patients with IMID without DM, atrial fibrillation had a similar effect as ischemic heart disease.</p><p><strong>Conclusion: </strong>The risk of HF hospitalization is increased in patients with IMID compared to the general population.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"East Meets West: A Canadian Rheumatology Resident's Experience in Hong Kong.","authors":"Alan L Zhou, Shirley C W Chan","doi":"10.3899/jrheum.2025-0093","DOIUrl":"10.3899/jrheum.2025-0093","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mathurin Maillet, Babacar S Tounkara, Damien Vagner, Kelly Bagny, Sébastien Duquenne, Céline Lartigau-Roussin, Anne Kolbe, Yves Lauret, Andry Randrianjohany, Serge Laureau, Nicole Denat, Aude Alquier, Nathalie Sultan-Bichat, Antoine Bertolotti, Loïc Raffray
{"title":"Epidemiology of Isolated Cutaneous Lupus Erythematosus in the Multiethnic Population of Reunion Island: A Retrospective Multicenter Study.","authors":"Mathurin Maillet, Babacar S Tounkara, Damien Vagner, Kelly Bagny, Sébastien Duquenne, Céline Lartigau-Roussin, Anne Kolbe, Yves Lauret, Andry Randrianjohany, Serge Laureau, Nicole Denat, Aude Alquier, Nathalie Sultan-Bichat, Antoine Bertolotti, Loïc Raffray","doi":"10.3899/jrheum.2024-0661","DOIUrl":"10.3899/jrheum.2024-0661","url":null,"abstract":"<p><strong>Objective: </strong>Few data are available about the epidemiology of cutaneous lupus erythematosus (CLE) in the Southern hemisphere and in multiethnic populations. We describe the prevalence, incidence, and clinical characteristics of isolated CLE in the multiethnic population of Reunion Island, France, including patients with dark skin.</p><p><strong>Methods: </strong>The study was performed in all public hospitals and private dermatology practices in Reunion Island. Cases were identified through informatics databases. Cases were defined as isolated CLE, meaning they did not fulfill the criteria for systemic lupus erythematosus (SLE). Incident cases were collected from 2008 to 2021. Prevalence was calculated on January 1, 2022. A capture-recapture analysis was performed to estimate both prevalence and incidence.</p><p><strong>Results: </strong>A total of 268 cases of CLE were identified and 218 were incident cases. The standardized prevalence of CLE was 43 out of 100,000 persons and the average annual standardized incidence was 3.1 per 100,000 person-years (PY). With a capture-recapture analysis, prevalence and annual incidence were estimated to be 99 out of 100,000 persons (95% CI 77.10-136.45) and 5.7 per 100,000 PY (95% CI 4.40-7.95), respectively. The mean age at diagnosis was 41.7 years and the ratio of female to male individuals was 4:1. Patients with dark skin had a higher rate of discoid CLE and were more likely to receive immunosuppressants. Generalized discoid CLE, panniculitis, and overlapping subtypes of CLE appeared as predictive markers of progression toward SLE.</p><p><strong>Conclusion: </strong>The prevalence and incidence of CLE in the multiethnic population of Reunion Island seem higher than in light-skinned populations. We highlight new risk factors of evolution toward SLE that should be known by practitioners to adjust follow-up.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"251-256"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cipriano R Gama, Andre S Franco, Adriana B Bortoluzzo, Renata Miossi, Ana Cristina Medeiros-Ribeiro, Ana Paula Luppino Assad, Percival D Sampaio-Barros
{"title":"Characteristics of Overlap Syndrome in a Large Cohort of Brazilian Patients With Systemic Sclerosis: A Retrospective Analysis.","authors":"Cipriano R Gama, Andre S Franco, Adriana B Bortoluzzo, Renata Miossi, Ana Cristina Medeiros-Ribeiro, Ana Paula Luppino Assad, Percival D Sampaio-Barros","doi":"10.3899/jrheum.2024-0505","DOIUrl":"10.3899/jrheum.2024-0505","url":null,"abstract":"<p><strong>Objective: </strong>Systemic sclerosis (SSc) often presents alongside other connective tissue disorders, termed \"overlap syndrome (OS).\" This study aimed to characterize patients with SSc with OS compared to those without OS in a tertiary university hospital in Brazil.</p><p><strong>Methods: </strong>A retrospective analysis of demographic, clinical, and laboratory data from 787 SSc patients was performed using electronic medical records. Patients were classified based on the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for SSc and additional criteria for systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), Sjögren disease (SjD), and rheumatoid arthritis (RA). Statistical analysis, including univariate and multivariate methods, identified factors associated with OS.</p><p><strong>Results: </strong>Ninety-one patients (11.6%) had OS, mainly with SLE (29.7%), SjD (26.4%), RA (24.2%), or IIM (19.8%). Patients with OS were younger, with an earlier age at onset (<i>P</i> = 0.004) and at diagnosis (<i>P</i> = 0.003). They presented a higher prevalence of limited SSc (<i>P</i> <sub>trend</sub> = 0.06), musculoskeletal symptoms (<i>P</i> < 0.001), neoplasia (<i>P</i> = 0.03), and sicca symptoms (<i>P</i> < 0.001); and were associated with a lower frequency of pulmonary hypertension (<i>P</i> = 0.048) and comorbidities such as diabetes mellitus (<i>P</i> = 0.02) and dyslipidemia (<i>P</i> = 0.02). A higher prevalence of anti-Ro (<i>P</i> = 0.007) and a lower prevalence of anti-Scl70 (<i>P</i> = 0.003) were also observed. Patients with OS were more frequently prescribed glucocorticoids (GCs; <i>P</i> < 0.001), methotrexate (<i>P</i> = 0.01), and leflunomide (<i>P</i> = 0.001). Multivariate analysis identified limited SSc (odds ratio [OR] 3.1), neoplasia (OR 3.4), and use of GCs (OR 8.2) and leflunomide (OR 5.5) with OS. No worse prognosis was observed.</p><p><strong>Conclusion: </strong>Overall, Brazilian patients with SSc with OS have distinct clinical characteristics but do not have a worse prognosis compared to those without OS.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tania Aguila, Riya Madan, Matthew B Palmer, Chris T Derk
{"title":"Zebra Bodies in Kidney Biopsy: Drug-Induced Phospholipidosis in a Patient With Systemic Lupus Erythematosus.","authors":"Tania Aguila, Riya Madan, Matthew B Palmer, Chris T Derk","doi":"10.3899/jrheum.2024-1312","DOIUrl":"10.3899/jrheum.2024-1312","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}